WHO

Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Friday, October 15, 2021 - 9:11pm

Phase 3 clinical data and real-world data both demonstrated the Johnson & Johnson single-shot COVID-19 vaccine was strong and long-lasting.

Key Points: 
  • Phase 3 clinical data and real-world data both demonstrated the Johnson & Johnson single-shot COVID-19 vaccine was strong and long-lasting.
  • "Johnson & Johnson is steadfast in its commitment to protect as many people globally as possible against the continued spread of COVID-19," said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.
  • You should not get the Janssen COVID-19 Vaccine if you:
    had a severe allergic reaction to any ingredient of this vaccine.
  • You should seek medical attention right away if you have any of the following symptoms after receiving Janssen COVID-19 Vaccine:

OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)

Friday, October 15, 2021 - 12:03pm

Canadians living with PAH, a rare disease for which there is no cure, now have a new treatment option.

Key Points: 
  • Canadians living with PAH, a rare disease for which there is no cure, now have a new treatment option.
  • OPSYNVIshould be used in patients who are currently treated concomitantly with stable doses of macitentan 10mg and tadalafil 40mg (20mg x 2) as separate tablets.
  • If left untreated, PH can lead to right ventricle failure, a serious type of heart failure.
  • As a combination therapy, OPSYNVI conveniently offers two therapies in one daily pill simplifying treatment for patients."

$15.4B Sodium Hyaluronate-based Products Market Outlook, 2028 - Plump Opportunities as Demand for Dermal Fillers Increases - ResearchAndMarkets.com

Friday, October 15, 2021 - 11:44am

The global sodium hyaluronate-based products market is expected to reach USD 15.4 billion by 2028, expanding at a CAGR of 7.5% from 2021 to 2028.

Key Points: 
  • The global sodium hyaluronate-based products market is expected to reach USD 15.4 billion by 2028, expanding at a CAGR of 7.5% from 2021 to 2028.
  • Sodium hyaluronate (NaHA) is more soluble than hyaluronic acid, along with having smaller molecules and greater skin penetration.
  • Some of the FDA-approved sodium hyaluronate dermal fillers available in the market are Restylane Defyne, Refyne, and Restylane.
  • Single-phase products and duplex products of hyaluronic acid are premium-priced products, and thus, they are not accessible to all patients.

Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine

Friday, October 15, 2021 - 11:19am

TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.

Key Points: 
  • TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.
  • Participants were administered intramuscularly two doses of either MVC-COV1901 or placebo 28 days apart.
  • In both younger and older adults who received the MVC-COV1901 vaccine, almost all participants had seroconversion in younger adults and 995% in older adults.
  • About Medigen Vaccine Biologics Corp. (MVC)
    MVC is a biopharmaceutical company using cell-based technologies to develop novel vaccines and biosimilars.

Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine

Friday, October 15, 2021 - 10:17am

TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.

Key Points: 
  • TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (MVC) data from its MVC-COV1901 vaccine phase 2 clinical trial which demonstrates promising immunogenicity and safety profiles.
  • Participants were administered intramuscularly two doses of either MVC-COV1901 or placebo 28 days apart.
  • In both younger and older adults who received the MVC-COV1901 vaccine, almost all participants had seroconversion in younger adults and 995% in older adults.
  • About Medigen Vaccine Biologics Corp. (MVC)
    MVC is a biopharmaceutical company using cell-based technologies to develop novel vaccines and biosimilars.

No Clean Slate for WHO’s Second COVID Probe, Says AHF

Thursday, October 14, 2021 - 8:23pm

AIDS Healthcare Foundation strongly objects to the repeat participation of Koopmans and other members of the first probe in the new investigation.

Key Points: 
  • AIDS Healthcare Foundation strongly objects to the repeat participation of Koopmans and other members of the first probe in the new investigation.
  • Koopmans recent comments are conspicuously inconsistent with the statements made at the tightly controlled press conference in Wuhan.
  • Ben Embarek has since also qualified his previously strong anti-lab leak position as open to further consideration.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20211014006051/en/

International Federation of Fertility Societies Supports Individuals Globally with Fertility Plans During the Pandemic

Thursday, October 14, 2021 - 7:00pm

MOUNT ROYAL, N.J., Oct. 14, 2021 /PRNewswire-PRWeb/ -- The International Federation of Fertility Societies (IFFS) created a global infographic campaign aimed at providing support to individuals around the world who are looking to safely start or resume their fertility plans during the COVID-19 Pandemic.

Key Points: 
  • MOUNT ROYAL, N.J., Oct. 14, 2021 /PRNewswire-PRWeb/ -- The International Federation of Fertility Societies (IFFS) created a global infographic campaign aimed at providing support to individuals around the world who are looking to safely start or resume their fertility plans during the COVID-19 Pandemic.
  • IFFS saw the need for information that reaches a global audience, thus creating the infographics offered in a variety of languages.
  • The Federation will be monitoring and utilizing the hashtag #THINKINGOFHAVINGABABY and encourage like-minded organizations to do the same when sharing the materials.
  • IFFS represents over 65 UN country specific fertility societies that in the aggregate, encompass an estimated 50,000 physicians and reproduction medicine specialists worldwide including various healthcare professionals.

Global Oncology Based In-vivo CRO Market Research & Analysis Report 2021-2028 - ResearchAndMarkets.com

Thursday, October 14, 2021 - 5:55pm

The "Global Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report by Indication (Blood Cancer, Solid Tumor), by Model (Syngeneic Model, Patient Derived Xenograft (PDX), Xenograft), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report by Indication (Blood Cancer, Solid Tumor), by Model (Syngeneic Model, Patient Derived Xenograft (PDX), Xenograft), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global oncology based in-vivo CRO market is expected to reach USD 1.9 billion by 2028 and is expected to expand at a CAGR of 8.2% from 2021 to 2028.
  • The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.
  • Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.

DGAP-News: Polyus Finance Plc: Closing of USD 700 million Eurobonds offering

Thursday, October 14, 2021 - 5:11pm

THE SECURITIES ARE NOT INTENDED FOR "OFFERING", "PLACEMENT" OR "CIRCULATION" (EACH AS DEFINED IN RUSSIAN SECURITIES LAWS) IN THE RUSSIAN FEDERATION, EXCEPT AS PERMITTED BY RUSSIAN LAW.

Key Points: 
  • THE SECURITIES ARE NOT INTENDED FOR "OFFERING", "PLACEMENT" OR "CIRCULATION" (EACH AS DEFINED IN RUSSIAN SECURITIES LAWS) IN THE RUSSIAN FEDERATION, EXCEPT AS PERMITTED BY RUSSIAN LAW.
  • Polyus Finance plc (the "Issuer"), an indirect wholly-owned finance subsidiary of PJSC Polyus (LSE, MOEX - PLZL) ("Polyus", the "Company") announces that the Issuer has closed and settled the issuance of USD 700 million notes due 14 October 2028 with a coupon of 3.25% per annum (the "Notes").
  • The Notes are guaranteed by PJSC Polyus and Joint Stock Company Polyus Krasnoyarsk, a wholly-owned subsidiary of the Company.
  • Forward-looking statements include statements relating to future capital expenditures and business and management strategies and the expansion and growth of Polyus' and/or Polyus group's operations.

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Thursday, October 14, 2021 - 2:00pm

The trial formally launches the expansion of the companys clinical development program for niclosamide into indications for inflammatory bowel diseases.

Key Points: 
  • The trial formally launches the expansion of the companys clinical development program for niclosamide into indications for inflammatory bowel diseases.
  • Patient screening is underway at clinical trial sites in Italy and will start soon in Austria and Germany.
  • First Wave BioPharma is also planning a separate clinical trial to investigate an oral formulation of niclosamide as a potential treatment for pancolitis.
  • FW-UP is a niclosamide-based, small molecule anti-inflammatory inhibitor therapy for the treatment of ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS).